Although somatically acquired genomic alterations have long been recognized as the hallmarks of acute lymphoblastic leukemia (ALL), the last decade has shown that inherited genetic variations (germline) are important determinants of inter-patient variability in ALL susceptibility, drug response, and toxicities of ALL therapy. In particular, unbiased genome-wide association studies (GWAS) have identified germline variants strongly associated with the predisposition to ALL in children, providing novel insights into the mechanisms of leukemogenesis and evidence for complex interactions between inherited and acquired genetic variations in ALL. Similar genome-wide approaches have also discovered novel germline genetic risk factors that independently influence ALL prognosis and those that strongly modify host susceptibility to adverse effects of antileukemic agents (e.g., vincristine, asparaginase, glucocorticoids). There are examples of germline genomic associations that warrant routine clinical use in the treatment of childhood ALL (e.g., TPMT and mercaptopurine dosing), but most have not reached this level of actionability. Future studies are needed to integrate both somatic and germline variants to predict risk of relapse and host toxicities, with the eventual goal of implementing genetics-driven precision medicine approaches in ALL treatment.
Introduction
Acute lymphoblastic leukemia (ALL) is the most common cancer in children, accounting for 25% of all childhood malignancies.
1,2 Sentinel chromosomal abnormalities (translocations or aneuploidy) are characteristic of the majority of ALL cases, and recent genomic profiling of leukemic cells continues to broaden our appreciation of the complex genomic landscape of this disease. [3] [4] [5] [6] These somatically acquired genomic aberrations are unique to ALL tumor cells; however, patients also carry inherited genetic variations (i.e., germline variants) that are present in both normal and tumor cells.
Although somatic genomic alterations have long been recognized as the hallmarks of ALL subtype classification, the last decade has shown that germline genetic variations are important determinants of inter-patient variability in ALL susceptibility, drug response, and toxicities of ALL therapy ( Table 1) .
Common types of inherited genetic variation include single nucleotide polymorphisms (SNPs), insertions and deletions (gain or loss of short segments of sequence or indels), and structural variations (gain or loss of large segments of sequence, e.g., copy number changes). Practically, non-malignant cells from patients (e.g., peripheral blood cells obtained during clinical remission) generally serve as the primary source of "germline"
DNA. Recent advances in high-throughput genotyping technology enable agnostic screens of genetic variation across the entire human genome, with up to a few million genetic markers tested per patient. These "genome-wide" association studies, often referred to as GWAS, do not rely on prior knowledge to focus on any subset of genes,
For personal use only. on September 24, 2017. by guest www.bloodjournal.org From but instead systematically examine genetic variations in an unbiased fashion for their association with the phenotype of interest. 7 Because of the large number of variants tested in GWAS, the required level of significance for association between a variant and a phenotype is generally set very high (P<5×10 -7 ) rather than the typical level of 5% for most power calculations. 8, 9 Thus, it is not surprising that there is limited power to detect genotype-phenotype associations using genome-wide approaches, and only genomic variation with great impact (large effect sizes) can be expected in most ALL GWAS. For example, with a sample size of 1,000 patients, at an alpha level of 5×10 -7 , a frequency of the genomic variant in the population of 10%, and a phenotype with that occurs in just 5% of patients (e.g., such
as central nervous system relapse of ALL or ALL therapy-related pancreatitis), in order to have 80% power to detect the genotype-phenotype association, the genomic variant would need to confer 4.5-fold higher risk of the trait than the "wild-type" or normal allele.
For phenotypes or alleles that are less common, effect sizes would have to be even higher than 4.5-fold (or the sample size would need to be greater). Thus, in discovery studies, every effort must be made to minimize variation in non-genetic risk factors and to maximize sample size, in order to improve the chance of observing associations between genomic variation and the phenotype of interest.
It should also be noted that commercial genotyping platforms that have been used in GWAS predominantly focus on relatively common genomic variants to achieve an even representation across all chromosomes ,although with varying degrees of coverage and resolution. 10 Most of these variants are intronic and may not be directly functional,
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11 As a result, findings from GWAS often require extensive follow-up studies to discover the true causal genetic variants underlying the GWAS signal. While SNPs are the primary focus of GWAS, copy number variations can also be detected by most genome-wide SNP chip/arrays 12 (except for small indels, e.g., promoter repeats in TYMS).
Inherited genetic basis of ALL susceptibility
The risk of developing ALL is highest between 2 and 5 years after birth, with initiating sentinel somatic genomic lesions (e.g., translocations) detectable at the time of birth in many cases. 13, 14 This early disease onset suggests a strong inherited genetic basis for ALL susceptibility. Inherited genetic risk factors for cancer can be divided into two main classes: rare penetrant variants associated with a high risk (may be observed in families with multiple members affected by ALL); and common less penetrant variants associated with a modestly increased risk of ALL (such as those observed in population studies of ALL risk).
Rare germline mutations and familial ALL
A number of inherited genetic variants have been identified in excess in rare cases of familial ALL. For example, 50% of children with low-hypodiploid ALL have germline TP53 mutations characteristic of Li-Fraumeni syndrome, 15 an autosomal dominant familial cancer syndrome characterized by a range of other solid and brain tumors.
Germline mutations of PAX5, which encodes a transcriptional factor required for B cell differentiation, were also found in two unrelated kindreds, each of which had 5 family
For personal use only. on September 24, 2017. by guest www.bloodjournal.org From members develop ALL. 16 However, the vast majority of childhood ALL is not familial, and TP53 or PAX5 mutations represent a very small population attributable risk (i.e.,
proportion of ALL cases that can be explained by these risk factors).
Common variants and susceptibility to childhood ALL Common genetic variants influencing leukemia susceptibility can be identified by association studies comparing the frequency of variations in unrelated ALL cases vs.
individuals not affected by ALL (controls), and variants over-represented in cases may contribute to the risk of developing this disease (examples given in Table 1 ). There is an extensive body of work to examine the contribution of a number of "candidate"
pathways (e.g., carcinogen metabolism, folate metabolism, DNA repair) to ALL risk, but with often times conflicting results. A recent meta-analysis summarized 47 studies of 25 polymorphisms in 16 genes and observed statistically significant (P<0.05) albeit modest associations with ALL susceptibility for 8 variants (e.g., CYP1A1*2A and XRCC1
G28152A)
. 17 However, it should be noted that the false-positive probability in this study was estimated at 20%. Similar pooled analyses subsequently confirmed the association for multiple variants in CYP1A1 and XRCC1, 18, 19 although with some variability by ancestry and age. Several epidemiology studies noted significant associations between infection and risk of ALL in children, pointing to potential roles of host immune defense in ALL etiology. [20] [21] [22] In fact, germline SNPs at the HLA-DP and HLA-DOA loci were associated with ALL susceptibility in admixed populations in the US. 23, 24 However, a comprehensive analysis of the major histocompatibility complex region in 824 B-ALL cases and 4,737 controls of European genetic ancestry did not find statistically significant associations signals in this genomic region after correcting for multiple Future functional studies are needed to describe the details of these molecular processes.
Germline genetic variation and ALL treatment outcome
While the survival rates of childhood ALL increased significantly in the past few decades due to risk-directed therapy, there is still substantial variation in treatment response, with 15% of children with ALL experiencing relapse. 41 In fact, relapse is the 5 th most common cancer in children and a leading cause of death in ALL. The inter-individual variation in relapse risk can arise from both tumor-and host-related factors. Gene expression profiling and more recently whole-genome sequencing studies discovered tumor genetic features associated with outcome and drug resistance. 15, [42] [43] [44] In parallel, there are increasing evidences that inherited genetic variations play important roles in determining patient's risk of relapse (Table 1) .
Candidate genes related to response to ALL therapy Inherited genetic variation can contribute to ALL treatment response by influencing host disposition of anti-leukemic agents, interactions between ALL and tumor, and tumor biology itself. In particular, it was widely hypothesized that variation in genes involved in Broader genomic studies, using a platform directed at cardiovascular variants, identified that HAS3 predisposed to cardiomyopathy, most strongly in those exposed to higher anthracycline doses. 90 These findings illustrate the principle that pharmacogenetic risk factors may be highly dependent on the exact therapeutic regimen, with some genetic risk factors most evident at lower drug doses and others most evident at higher drug doses.
Vincristine
Vincristine neuropathy can be a major dose-limiting adverse effect in ALL. In a genomewide study, a higher frequency of neuropathy has been associated with a promoter variant in CEP72 (rs924607 to permit routine use as a clinical test. However, the field is likely to change as new data emerge over the next few years especially with the rapid advances in next-generation sequencing which raises the exciting possibility of exhaustively interrogating all variants in the genome (e.g., rare variants with large effects).
Ultimately, one can foresee that both somatically acquired ALL-specific genetic alterations as well as inherited genomic variants will be used to predict each patient's risk of relapse and of host toxicities with differing treatment regimens, and the choice of treatment protocol can be informed by balancing the probability of cure vs the probability of adverse effects based on genetic and other patient characteristics. For example, patients carrying highly penetrant germline variants related to life-threatening toxicities (pancreatitis) may be considered for treatment regimens that are not highly dependent on asparaginase, especially if his/her germline and/or tumor genetic profiles indicate sensitivity to other chemotherapeutics. Conversely, optimizing antileukemic effect is weighted more in patients with high-risk ALL, particularly if they are predicted to experience modest toxicities based on germline genetic variations. The delicate balance between toxicity and efficacy in this context is challenging 110 , and large collaborations are needed to comprehensively evaluate outcome-or toxicity-related genetic variants in diverse treatment regimens and to develop genetics-based decision support systems,.
Childhood ALL is uniquely positioned for this type of translational research given the impressive progress already made in genomics and pharmacogenomics of this disease and the exceptionally organized clinical trials for children with ALL. Candidate gene thiopurine induced myelosuppression
